Circulating CD147 predicts mortality in advanced hepatocellular carcinoma.

By | August 30, 2015

Lee A, Rode A, Nicoll A, Maczurek AE, Lim L, Lim S, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Warner FJ, McCaughan GW, McLennan SV, Shackel NA

Related Articles

Circulating CD147 predicts mortality in advanced hepatocellular carcinoma.

J Gastroenterol Hepatol. 2015 Aug 27;

Authors: Lee A, Rode A, Nicoll A, Maczurek AE, Lim L, Lim S, Angus P, Kronborg I, Arachchi N, Gorelik A, Liew D, Warner FJ, McCaughan GW, McLennan SV, Shackel NA

Abstract
BACKGROUND AND AIMS: The glycoprotein CD147 has a role in tumor progression, is readily detectable in the circulation and is abundantly expressed in HCC. Advanced HCC patients are a heterogeneous group with some individuals having dismal survival. The aim of this study was to examine circulating soluble CD147 levels as a prognostic marker in HCC patients.
METHODS: CD147 was measured in 277 patients (110 HCC, 115 chronic liver disease and 52 non-liver disease). Clinical data included etiology, tumor progression, Barcelona Clinic Liver Cancer (BCLC) stage and treatment response. Patients with HCC were stratified into two groups based upon the 75(th) percentile of CD147 levels (24 ng/mL).
RESULTS: CD147 in HCC correlated inversely with poor survival (P = 0.031). Increased CD147 predicted poor survival in BCLC stages C and D (P = 0.045) and CD147 levels > 24 ng/mL predicted a significantly diminished 90-day and 180-day survival time (hazard ratio (HR) = 6.1; 95% confidence interval (CI):2.1-63.2; P = 0.0045 and HR = 2.8; 95% CI:1.2-12.6; P = 0.028, respectively). In BCLC stage C, CD147 predicted prognosis; levels > 24 ng/mL were associated with a median survival of 1.5 months compared to 6.5 months with CD147 levels ≤ 24 ng/mL (P = 0.03). CD147 also identified patients with a poor prognosis independent from treatment frequency, modality and tumor size.
CONCLUSIONS: Circulating CD147 is an independent marker of survival in advanced HCC. CD147 requires further evaluation as a potential new prognostic measure in HCC to identify patients with advanced disease who have a poor prognosis. This article is protected by copyright. All rights reserved.

PMID: 26312403 [PubMed – as supplied by publisher]

Category: Uncategorized

Leave a Reply

Your email address will not be published. Required fields are marked *